Homepage | CIDRAP
WEBThe Influenza Vaccines Roadmap provides a much-needed framework for organizing the efforts of existing influenza researchers while identifying a wide range of opportunities that will encourage new investigators to join the work.
COVID-adapted stewardship intervention linked to reduced
WEB1 day ago · Jordi Mora Igual / iStock. Incorporating COVID-19–specific elements into an existing antimicrobial stewardship program (ASP) framework was associated with reduced antibiotic use and resistance at a safety-net hospital in Chicago, researchers reported today in Antimicrobial Stewardship & Healthcare Epidemiology.. COVID-19 posed a significant diagnostic challenge for clinicians in the early ...
COVID-19 - CIDRAP
WEBNew report: COVID more severe, longer-lasting than other respiratory diseases. COVID-19 participants most often reported fatigue, muscle aches, headache, and loss of taste and/or smell, consistent with the more extensive systemic COVID-19 effects. Mary Van Beusekom.
Study forecasts more than 39 million deaths from antimicrobial ...
WEB1 day ago · Antibiotic-resistant bacterial infections could take the lives of more than 39 million people by 2050 unless action is taken to improve healthcare quality, prevent infections, reduce inappropriate antibiotic use, and develop new antibiotics, according to a landmark new study published this week in The Lancet.. The modeling study by researchers with the Global Research on Antimicrobial ...
Global health experts note improved post-COVID pandemic
WEB2 days ago · A new survey among leading global infectious disease experts conducted by Abbott shows that most experts agree that pandemic preparedness has improved since the COVID-19 pandemic, but significant gaps remain in building surveillance programs to identify emerging pathogens, public health funding, and adequate testing infrastructure.. The Abbott Pandemic Defense Coalition asked 103 ...
About CIDRAP | CIDRAP
WEBThe Center for Infectious Disease Research and Policy (CIDRAP; "SID-wrap") is a global leader in addressing public health preparedness and emerging infectious disease response. Founded in 2001, CIDRAP is part of the Research and Innovation Office at the University of Minnesota. CIDRAP works to prevent illness and death from targeted infectious ...
Evidence growing for COVID antivirals to cut poor outcomes
WEB2 days ago · A recently published systematic review and meta-analysis found no evidence that the antiviral drugs nirmatrelvir/ritonavir (Paxlovid) and molnupiravir (Lagevrio) help prevent COVID-19 hospitalization, death, or persistent symptoms, results that the authors say call for reassessment of the role that oral antivirals play in the context of currently circulating SARS-CoV-2 variants and population ...
CIDRAP in the News
WEBAug 15, 2024 In Foreign Affairs, Director Michael Osterholm, PhD, MPH, and coauthor Mark Olshaker discuss how governments and international organizations have done far too little to prepare for the next pandemic-causing virus.. Jul 2, 2024 CIDRAP releases two new Research and Development Roadmaps: one for developing tools to combat Nipah virus and the other for tools to combat Lassa fever.
CIDRAP to develop vaccine roadmap for future coronavirus threats
WEBOver the past few years, health groups have tapped CIDRAP to develop similar vaccine roadmaps for influenza, Zika virus, Nipah virus and Ebola/Marburg viruses. Michael T. Osterholm, PhD, MPH, CIDRAP's director, said current COVID-19 vaccines may not protect against future SARS-CoV-2 variants, and the threat of a novel virus spillover looms in ...
COVID-19: CIDRAP Commentaries
WEBCOVID-19: The CIDRAP Viewpoint. Starting at the beginning of the pandemic, CIDRAP compiled a groundbreaking of series of reports on key aspects of COVID-19, such as what direction the pandemic might take, how to communicate risks effectively, smart testing for the virus and for antibodies to it, contact tracing, surveillance, ensuring a ...